Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Merck

The size of the pharmaceutical industry in the U.S. in 2023 was estimated to be nearly $575 billion, with an anticipated compound growth rate of about 5.5% through 2030. This key component of the healthcare sector includes both small biotech firms working to develop specialized treatments and much larger, established companies engaging in a wide array of health-related operations.

Best Pharma Stocks for Long-Term Investors: Growth and Dividends

Johnson & Johnson's Q3 2024 earnings report will highlight its MedTech division, driven by strategic acquisitions and R&D investments in cardiovascular and orthopedic solutions. Despite lagging behind the S&P in price growth, JNJ offers a solid income investment with a 3.09% dividend yield and steady financials. Risks include short-term costs from acquisitions, supply chain issues in the Vision division, and external pressures like currency fluctuations and competition.

Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth

Fortis

Coca-Cola

Dividend stocks are among the top assets long-term investors want to consider when it comes to building a stable income-generating portfolio over time.

Retirees: Focus on Dividend Growth With These 3 Stocks

Johnson & Johnson stock (NYSE: JNJ) will report its Q3 2024 results on Tuesday, October 15. We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning with the consensus estimates of $22.1 billion and $2.19, respectively.

What Trends Will Drive Johnson & Johnson's Q3 Results?

Kyndryl Holdings

Johnson & Johnson (JNJ) reports earnings Tuesday morning for the third quarter, with analysts expecting the company's revenue and profit to rise year-on-year.

What You Need to Know Ahead of Johnson & Johnson's Earnings

A Johnson & Johnson subsidiary can pursue its third attempt to resolve tens of thousands of lawsuits alleging its talc products caused cancer in a Texas bankruptcy court, a judge ruled on Thursday, allowing the company to avoid a venue that shot down its two previous efforts.

J&J talc bankruptcy stays in Texas despite 'forum-shopping" opposition

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Stifel 2024 Healthcare Conference on Monday, November 18th, at the Lotte New York Palace in New York. Michael Bodner, Group President, Heart Recovery & Circulatory Restoration, will represent the Company in a session scheduled at 10:55 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.inve.

Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference

JNJ's current dividend yield is around the highest level in at least 10 years. The market's concern over its current issues - which are all temporary in my view - is drastically overblown. The overreaction has created a severe mispricing for this sector leader with superb financial strength and stable growth outlook.

Johnson & Johnson: You Need To Look At This Chart (Rating Upgrade)

Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

TREMFYA ®  is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory  Ninety percent more biologic-naïve  patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA ®   VIENNA, Austria , Oct. 10, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced TREMFYA® (guselkumab) data in both Crohn's disease (CD) and ulcerative colitis (UC) showing high rates of endoscopic remission in both biologic-naïve and biologic-refractory patients (including UC patients refractory to JAK inhibitors), indicating a normal appearance of intestinal mucosa.1,2 These subgroup analyses are from pooled data from the Phase 3 GALAXI 2 & 3 studies of TREMFYA® in adults with moderately to severely active CD and the Phase 3 QUASAR maintenance study of TREMFYA® in adults with moderately to severely active UC. These findings are among 19 Johnson & Johnson abstracts being presented at the United European Gastroenterology (UEG) Week 2024.

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy1

Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients

Archer-Daniels-Midland Company

Amcor Plc

Franklin Resources

Chevron

Con Ed

Fastenal

Federal Realty Investment Trust

Genuine Parts

Hormel Foods

Kenvue

Medtronic

Realty Income Corp

PepsiCo

J. M. Smucker

Solventum Corporation

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

Walgreens

"Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 10.5%-20.13% topped-by Franklin & Target.

Buy 4 October Dividend Aristocrats & Watch 10

Johnson & Johnson (JNJ, Financial) has finalized the acquisition of V-Wave Ltd, a private medical device company. The pharmaceutical giant agreed to purchase V-Wave for an upfront payment of $600 million.

Johnson & Johnson (JNJ) Completes Acquisition of V-Wave Ltd for $600 Million

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech. The acquisition of V-Wave extends Johnson & Johnson MedTech's position in cardiovascular disease and provides an even greater opportunity to tackle heart failure, one of the.

Johnson & Johnson Completes Acquisition of V-Wave

Procter & Gamble

When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield.

Should Investors Consider High Yield Dividend Stocks?

Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.

What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for

ABM Industries

Abbott Labs

American States Water

Becton, Dickinson and Co.

Black Hills

Commerce Bancshares

Cincinnati Financial

Colgate-Palmolive

California Water Service Group

Dover

Emerson Electric

H.B. Fuller

Gorman-Rupp

W.W. Grainger

Illinois Tool Works

Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for potential investment. The article provides tables and charts presenting quality scores, key metrics, and fair value estimates.

News for Johnson & Johnson Stock (JNJ)